目的：观察依达拉奉、奥扎格雷联合克栓酶治疗急性脑卒中的临床疗效。方法选择2014年1月—2015年2月湖北医药学院附属太和医院收治的急性脑卒中患者60例，按照入院先后顺序将患者分为对照组和观察组，各30例。对照组患者采用依达拉奉和奥扎格雷进行治疗，观察组患者采用依达拉奉、奥扎格雷联合克栓酶进行治疗，两组患者均治疗2周。比较两组患者治疗前后神经功能缺损程度评分、美国国立卫生研究院卒中量表（ NIHSS）评分、日常生活活动能力量表（ ADL）评分及临床疗效。结果治疗前两组患者神经功能缺损程度评分、NIHSS评分及ADL评分比较，差异无统计学意义（ P>0.05）；治疗后观察组患者神经功能缺损程度评分、NIHSS评分低于对照组，ADL评分高于对照组（P<0.05）。观察组患者临床疗效优于对照组（u=2.530，P=0.011）。结论依达拉奉、奥扎格雷联合克栓酶治疗急性脑卒中的临床疗效确切，能有效改善患者神经功能缺损程度、提高患者日常生活能力。%Objective To observe the clinical effect of edaravone and ozagrel combined with defibrin on acute stroke. Methods From January 2014 to February 2015,a total of 60 patients with acute stroke were selected in Taihe Hospital Affiliated to Hubei Medicine College, and they were divided into control group and observation group according to the order of hospitalization,each of 30 cases. Patients of control group were given edaravone and ozagrel,while patients of observation group were given edaravone and ozagrel combined with defibrin,both groups treated for 2 weeks. Neurological deficit score,NIHSS score and ADL score before and after treatment and clinical effect were compared between the two groups. Results No statistically significant differences of neurological deficit score,NIHSS score or ADL score was found between the two groups before treatment(P>0. 05);after treatment,neurological deficit score and NIHSS score of observation group were statistically significantly lower than those of control group,while ADL score of observation group was statistically significantly higher than that of control group ( P <0. 05 ). The clinical effect of observation group was statistically significantly better than that of control group(u=2. 530,P=0. 011). Conclusion Edaravone and ozagrel combined with defibrin has certain clinical effect on acute stroke,which can effectively reduce the degree of nervous functional defects,improve the activity of daily living.
展开▼
